Can KUBTEC Scientific lower the barrier to image-guided radiotherapy in cancer research?

Preclinical IGRT is powerful but costly. KUBTEC Scientific’s XCELL TomoRad tests whether access, speed, and targeting can finally align.

Preclinical IGRT is powerful but costly. KUBTEC Scientific’s XCELL TomoRad tests whether access, speed, and targeting can finally align.